Movement Alert｜Alebund Pharmaceuticals-B Falls 7.56% in Regular Trading, Post-IPO Volatile Pattern Persists as Stock Retreats Over 40% From High

Market Focus07-13 09:48

On July 13, Alebund Pharmaceuticals-B fell 7.56% in regular trading, trading at 27.42 HKD/share, with turnover of HKD 2.1965 million.

The stock has experienced sharp volatility since listing on June 29 at an IPO price of 22.6 HKD. After surging over 103% on its debut, the stock underwent multiple rounds of rapid gains and declines. A previous disclosure that GIC and LAV collectively increased holdings by over 1.32 million shares (involving approximately HKD 59 million) drove a single-day gain exceeding 10% on July 8, but the stock has since retreated consecutively. The current price represents a pullback of over 40% from the first-day high of 46.82 HKD.

The company is an innovative pharmaceutical enterprise focused on kidney diseases. Its core product AP301 has entered the NDA sprint phase, approximately 12 to 24 months from commercialization. The low-volume decline indicates that selling pressure has not yet been fully released, as short-term profit-taking continues to weigh on the newly listed stock.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1172657278?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-13 09:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1172657278","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Alebund Pharmaceuticals-B Falls 7.56% in Regular Trading, Post-IPO Volatile Pattern Persists as Stock Retreats Over 40% From High","media":"Market Focus","content":"<p><p>On July 13, Alebund Pharmaceuticals-B fell 7.56% in regular trading, trading at 27.42 HKD/share, with turnover of HKD 2.1965 million.</p><p>The stock has experienced sharp volatility since listing on June 29 at an IPO price of 22.6 HKD. After surging over 103% on its debut, the stock underwent multiple rounds of rapid gains and declines. A previous disclosure that GIC and LAV collectively increased holdings by over 1.32 million shares (involving approximately HKD 59 million) drove a single-day gain exceeding 10% on July 8, but the stock has since retreated consecutively. The current price represents a pullback of over 40% from the first-day high of 46.82 HKD.</p><p>The company is an innovative pharmaceutical enterprise focused on kidney diseases. Its core product AP301 has entered the NDA sprint phase, approximately 12 to 24 months from commercialization. The low-volume decline indicates that selling pressure has not yet been fully released, as short-term profit-taking continues to weigh on the newly listed stock.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Alebund Pharmaceuticals-B Falls 7.56% in Regular Trading, Post-IPO Volatile Pattern Persists as Stock Retreats Over 40% From High</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Alebund Pharmaceuticals-B Falls 7.56% in Regular Trading, Post-IPO Volatile Pattern Persists as Stock Retreats Over 40% From High\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-13 09:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 13, Alebund Pharmaceuticals-B fell 7.56% in regular trading, trading at 27.42 HKD/share, with turnover of HKD 2.1965 million.</p><p>The stock has experienced sharp volatility since listing on June 29 at an IPO price of 22.6 HKD. After surging over 103% on its debut, the stock underwent multiple rounds of rapid gains and declines. A previous disclosure that GIC and LAV collectively increased holdings by over 1.32 million shares (involving approximately HKD 59 million) drove a single-day gain exceeding 10% on July 8, but the stock has since retreated consecutively. The current price represents a pullback of over 40% from the first-day high of 46.82 HKD.</p><p>The company is an innovative pharmaceutical enterprise focused on kidney diseases. Its core product AP301 has entered the NDA sprint phase, approximately 12 to 24 months from commercialization. The low-volume decline indicates that selling pressure has not yet been fully released, as short-term profit-taking continues to weigh on the newly listed stock.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09637","symbol_name":"礼邦医药-B","start_time":0,"source_url":"","article_id":"1172657278","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1172657278","pubTimestamp":1783907285,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 13, Alebund Pharmaceuticals-B fell 7.56% in regular trading, trading at 27.42 HKD/share, with turnover of HKD 2.1965 million.The stock has experienced sharp volatility since listing on June...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09637":"礼邦医药-B"},"translate_title":"走势警报|Alebund Pharmaceuticals-B 常规交易中下跌 7.56%，IPO 后波动模式持续，股价从高位回落超过 40%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09637":1},"content_text":"On July 13, Alebund Pharmaceuticals-B fell 7.56% in regular trading, trading at 27.42 HKD/share, with turnover of HKD 2.1965 million.The stock has experienced sharp volatility since listing on June 29 at an IPO price of 22.6 HKD. After surging over 103% on its debut, the stock underwent multiple rounds of rapid gains and declines. A previous disclosure that GIC and LAV collectively increased holdings by over 1.32 million shares (involving approximately HKD 59 million) drove a single-day gain exceeding 10% on July 8, but the stock has since retreated consecutively. The current price represents a pullback of over 40% from the first-day high of 46.82 HKD.The company is an innovative pharmaceutical enterprise focused on kidney diseases. Its core product AP301 has entered the NDA sprint phase, approximately 12 to 24 months from commercialization. The low-volume decline indicates that selling pressure has not yet been fully released, as short-term profit-taking continues to weigh on the newly listed stock.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1172657278","isCrawlerRequest":true}